HC Wainwright Issues Negative Estimate for UNCY Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Analysts at HC Wainwright reduced their Q4 2025 earnings per share (EPS) estimates for Unicycive Therapeutics in a report released on Thursday, November 13th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.35) per share for the quarter, down from their prior forecast of $0.50. HC Wainwright has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Unicycive Therapeutics’ Q1 2026 earnings at ($0.35) EPS, Q2 2026 earnings at ($0.30) EPS, Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.12) EPS, FY2026 earnings at ($0.94) EPS, FY2027 earnings at $1.71 EPS and FY2028 earnings at $6.03 EPS.

Several other research analysts have also weighed in on UNCY. Wall Street Zen upgraded shares of Unicycive Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, November 2nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Unicycive Therapeutics in a research note on Thursday, October 30th. Finally, Benchmark upped their price target on Unicycive Therapeutics to $21.00 and gave the stock a “speculative buy” rating in a report on Monday, September 15th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $34.33.

Unicycive Therapeutics Stock Up 2.6%

Shares of UNCY opened at $5.92 on Monday. Unicycive Therapeutics has a 52-week low of $3.71 and a 52-week high of $11.00. The company has a 50-day simple moving average of $4.59 and a 200-day simple moving average of $5.05. The company has a market capitalization of $127.22 million, a PE ratio of -1.50 and a beta of 1.87.

Unicycive Therapeutics (NASDAQ:UNCY) last released its earnings results on Wednesday, November 12th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.20.

Institutional Trading of Unicycive Therapeutics

Large investors have recently modified their holdings of the business. Lazard Asset Management LLC acquired a new position in shares of Unicycive Therapeutics during the 2nd quarter worth approximately $55,000. JPMorgan Chase & Co. increased its position in Unicycive Therapeutics by 11,698.4% during the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after buying an additional 21,525 shares in the last quarter. Citadel Advisors LLC acquired a new position in shares of Unicycive Therapeutics in the third quarter worth $182,000. Squarepoint Ops LLC purchased a new stake in shares of Unicycive Therapeutics in the third quarter valued at $512,000. Finally, Vanguard Group Inc. boosted its stake in shares of Unicycive Therapeutics by 8.7% during the third quarter. Vanguard Group Inc. now owns 658,878 shares of the company’s stock valued at $2,873,000 after acquiring an additional 52,925 shares during the last quarter. 40.42% of the stock is currently owned by institutional investors and hedge funds.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.